Integer Holdings Corporation Website

Integer Holdings Corporation

NYSE-ITGR

Company Overview

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

  • Name

    Integer Holdings Corporation

  • CEO

    Payman Khales

  • Website

    www.integer.net

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1970

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Integer Holdings Corp Shows Resilience Amidst Challenges in November

  • Management's optimistic outlook following a CEO transition bolstered investor confidence.
  • Legal developments favoring Integer Holdings Corp reinforced its competitive position within the med tech sector.
  • Despite regulatory scrutiny, strategic announcements contributed positively to stock performance.

Over the past month, Integer Holdings Corporation (ITGR) experienced a positive stock movement of 3.1%, significantly outperforming the S&P 500's return of 0.7%. This performance reflects notable resilience and strategic positioning within the medical technology sector, particularly after key developments that enhanced investor confidence.

A significant boost for ITGR came from management’s optimistic outlook following a CEO transition on December 3, when ITGR gained 0.5%. The leadership emphasized their commitment to enhancing shareholder value and leveraging Integer’s capabilities as a preferred partner in medical technology. Earlier in November, participation in major investor conferences hosted by Piper Sandler and Citi was announced; these events were anticipated to provide further visibility for the company.

However, not all news was favorable during this period; on November 19, bearish sentiment emerged due to an investigation into potential violations of federal securities laws. Although third-quarter results met expectations, ITGR revised its full-year outlook downward by $16 million due to slower adoption rates for new products like electrophysiology devices. This led to a temporary decline in stock price but did not overshadow overall positive trends throughout most of November.

Legal developments also played an important role in shaping market perceptions around ITGR. On November 11, it was reported that a federal judge rejected attempts by the FTC to block GTCR's acquisition involving Surmodics—a ruling viewed favorably as it allowed for partial divestiture benefiting Integer Holdings Corp., thereby reinforcing its competitive stance within the industry.

Overall, while challenges related to regulatory scrutiny and product adoption issues were present—reflected through bearish movements—bullish sentiments stemming from strategic announcements and favorable legal outcomes contributed positively to ITGR’s performance over this one-month period. Relative to benchmarks during this time frame, Integer Holdings Corp outperformed both the S&P 500 index by 2.4% and exceeded Health Care (XLV) sector performance by 1.1%.

NYSE:ITGR